Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI).

导出 OA

翻译打印收藏纠错

作者： Irene,Vanni ^[1] ; Milena,Casula ^[2] ; Lorenza,Pastorino ^[3] ; Antonella,Manca ^[1] ; Bruna,Dalmasso ^[2] ; Virginia,Andreotti ^[3] ; Marina,Pisano ^[1] ; Maria,Colombino ^[2] ; Italian Association for Cancer Research (AIRC) Study Group ^[1] ; Ulrich,Pfeffer ^[2] ; Enrica Teresa,Tanda ^[3] ; Carla,Rozzo ^[3] ; Panagiotis,Paliogiannis ^[4] ; Antonio,Cossu ^[5] ; Paola,Ghiorzo ^[3] ; Giuseppe,Palmieri ^[6] ; Italian Melanoma Intergroup (IMI) ^[3]

作者单位： Genetics of Rare Cancers, IRCCS Ospedale Policlinico San Martino, L.go R Benzi, 10, 16132, Genoa, Italy. ^[1] Genetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy. ^[2] Unit of Cancer Genetics, National Research Council (CNR), Sassari, Italy. ^[3] Tumor Epigenetics, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. ^[4] Medical Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. ^[5] Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy. ^[6] Genetics of Rare Cancers, IRCCS Ospedale Policlinico San Martino, L.go R Benzi, 10, 16132, Genoa, Italy. paola.ghiorzo@unige.it. ^[7] Genetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy. paola.ghiorzo@unige.it. ^[8]

关键词 BRAF Gene panel testing Melanoma Next generation sequencing (NGS)Quality controls Somatic mutations Target therapy